Literature DB >> 2859121

The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.

Y Ebina, L Ellis, K Jarnagin, M Edery, L Graf, E Clauser, J H Ou, F Masiarz, Y W Kan, I D Goldfine.   

Abstract

A cloned approximately 5 kb cDNA (human placenta) contains the coding sequences for the insulin receptor. The nucleotide sequence predicts a 1382 amino acid precursor. The alpha subunit comprises the N-terminal portion of the precursor and contains a striking cysteine-rich "cross-linking" domain. The beta-subunit (the C-terminal portion of the precursor) contains a transmembrane domain and, in the intracellular region, the elements of a tyrosine phosphokinase: an ATP-binding site and a possible tyrosine autophosphorylation site or sites. The overall structure is reminiscent of the EGF receptor; the cross-linking domain of the alpha subunit and several regions of the beta subunit exhibit sequence homology with the EGF receptor. The phosphokinase domain also exhibits homology with some oncogenic proteins that have tyrosine phosphokinase activity, in particular, a striking homology with v-ros. Southern blotting experiments suggest that the coding region spans more than 45 kb. The insulin receptor gene is located on chromosome 19.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859121     DOI: 10.1016/0092-8674(85)90334-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  333 in total

1.  APS, an adapter protein with a PH and SH2 domain, is a substrate for the insulin receptor kinase.

Authors:  Z Ahmed; B J Smith; K Kotani; P Wilden; T S Pillay
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

2.  Mutational analysis of the N-linked glycosylation sites of the human insulin receptor.

Authors:  T C Elleman; M J Frenkel; P A Hoyne; N M McKern; L Cosgrove; D R Hewish; K M Jachno; J D Bentley; S E Sankovich; C W Ward
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

Review 3.  Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.

Authors:  A Virkamäki; K Ueki; C R Kahn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

Review 4.  Post-transcriptional regulation in metabolic diseases.

Authors:  Wook Kim; Eun Kyung Lee
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

Review 5.  Insulin and insulin-like growth factor receptors in the nervous system.

Authors:  M Adamo; M K Raizada; D LeRoith
Journal:  Mol Neurobiol       Date:  1989 Spring-Summer       Impact factor: 5.590

6.  In vitro tyrosine phosphorylation studies on RAS proteins and calmodulin suggest that polylysine-like basic peptides or domains may be involved in interactions between insulin receptor kinase and its substrate.

Authors:  Y Fujita-Yamaguchi; S Kathuria; Q Y Xu; J M McDonald; H Nakano; T Kamata
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

7.  Another version of the human insulin receptor kinase domain: expression, purification, and characterization.

Authors:  M Villalba; S R Wente; D S Russell; J C Ahn; C F Reichelderfer; O M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

8.  The SPOT technique as a tool for studying protein tyrosine phosphatase substrate specificities.

Authors:  Xavier Espanel; Martine Huguenin-Reggiani; Rob Hooft van Huijsduijnen
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

9.  Erythroid differentiation factor is encoded by the same mRNA as that of the inhibin beta A chain.

Authors:  M Murata; Y Eto; H Shibai; M Sakai; M Muramatsu
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Effect of basic polycations and proteins on purified insulin receptor. Insulin-independent activation of the receptor tyrosine-specific protein kinase by poly(L-lysine).

Authors:  Y Fujita-Yamaguchi; D B Sacks; J M McDonald; D Sahal; S Kathuria
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.